SCHEMBL3900962

SCHEMBL3900962

COc1cc2c(cc1S(=O)(=O)Cl)CCN(C)CC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
SLC6A4 P31645 1/20 0.56
DRD1 P21728 3/20 0.49
DRD5 P21918 3/20 0.49
DRD4 P21917 2/20 0.49
MAPT P10636 2/20 0.49
CA7 P43166 1/20 0.49
DRD2 P14416 3/20 0.47
DRD3 P35462 3/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR6 P50406 1/20 0.47
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TRPV4 Q9HBA0 1/20 0.46
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PDE4D Q08499 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10641792 0.85 TRPV4 (0.50) MAPTCA7GAASMN1; SMN2TRPV4
SCHEMBL29652427 0.85 TRPV4 (0.50) MAOAMAOBSLC6A4MAPTCA7
SCHEMBL10575175 0.85 TRPV4 (0.50) MAOAMAOBSLC6A4MAPTCA7
Hydrochloric Acid SCHEMBL10350988 0.84 MAOA (0.56) MAOAMAOBSLC6A4DRD1DRD5
SCHEMBL3897270 0.84 MAOA (0.56) MAOAMAOBSLC6A4DRD1DRD5
SCHEMBL3906143 0.84 MAOA (0.56) MAOAMAOBSLC6A4DRD1DRD5
SCHEMBL10350477 0.84 CA7 (0.44) CA7SMN1; SMN2TRPV4MEN1KMT2A
SCHEMBL10767029 0.82 ABCB1 (0.62) MAPTTSHR
SCHEMBL10749047 0.81 TRPV4 (0.51) MAOBMAPTCA7DRD2DRD3
SCHEMBL31525653 0.80 TRPV4 (0.40) MAOAMAOBSLC6A4MAPTCA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504392-B2 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use GLAXO GROUP LIMITED (GB) 2009-03-17 US disclosed
US-20080269197-A1 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia GLAXO GROUP LIMITED 2008-10-30 US disclosed
US-20070275948-A1 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics GLAXO GROUP LIMITED (GB) 2007-11-29 US disclosed
US-20070093473-A1 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents GLAXO GROUP LIMITED 2007-04-26 US disclosed
EP-1511727-B1 AROMATIC SULFONES AND THEIR MEDICAL USE GLAXO GROUP LTD (GB) 2007-02-21 EP disclosed
EP-1687279-A1 7- [4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
EP-1663248-A1 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-06-07 EP disclosed
US-20050261279-A1 Compounds GLAXO GROUP LIMITED (GB) 2005-11-24 US disclosed
WO-2005051397-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed
WO-2005051916-A1 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed
WO-2005025576-A1 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-03-24 WO disclosed
WO-2005014578-A1 PHENYLSULFONYL COMPOUNDS AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269197-A1 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia SIGMAR1, CBR3, CBR1 MAOA 484/4885MAOB 291/4885SLC6A4 558/4885
US-20050261279-A1 Compounds CBR1, CBR3, OXER1 MAOA 2087/4885MAOB 2012/4885SLC6A4 3815/4885
US-20070093473-A1 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents SIGMAR1, CHRNA3, CHRNA5 MAOA 630/4885MAOB 444/4885SLC6A4 250/4885
US-20070275948-A1 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics TPMT, HTR4, HTR7 MAOA 1178/4885MAOB 484/4885SLC6A4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.